Can Wegovy Cause Blindness? What the Evidence Says

Step 1: Understanding the 2024 study that started the conversation

The concern about semaglutide and blindness stems primarily from a retrospective cohort study published in JAMA Ophthalmology in 2024, which reviewed US medical records and found that people taking semaglutide for weight management had a statistically higher rate of NAION compared with those taking other weight-loss medicines or diabetes treatments. The absolute numbers were still small (NAION itself is uncommon in the general population, affecting roughly 2–10 per 100,000 people per year) but the relative increase was notable enough to prompt wider discussion.

NAION occurs when blood flow to the optic nerve head is suddenly reduced, typically causing painless vision loss that tends to be permanent in the affected eye. It is not the same as gradual age-related sight loss; onset is usually rapid, often noticed on waking. Risk factors include a structurally small optic nerve head, high blood pressure, sleep apnoea, diabetes and obesity. That last point matters: the populations most likely to be prescribed semaglutide (people with obesity or type 2 diabetes) already sit at elevated baseline risk for the very condition researchers were measuring. Separating a drug signal from background risk in such a population is genuinely difficult, and the study's authors acknowledged this limitation clearly.

For a fuller look at what the research says specifically about whether semaglutide makes you blind, that page works through the mechanisms and study design in more detail.

Step 2: What regulators have (and have not) concluded

Following the JAMA Ophthalmology study, the US Food and Drug Administration reviewed the data and in July 2024 announced it would investigate whether a causal link exists. The MHRA, which licenses Wegovy in the UK, has been aware of the signal and continues to monitor post-market safety data through its Yellow Card scheme. As of summer 2026, Wegovy's UK prescribing information lists visual disturbance as a potential side effect to watch for, particularly in patients with diabetic eye disease, but NAION does not appear as a listed contraindication or formal warning for the weight-management indication.

That regulatory position is not a clean bill of health, it reflects the genuine difficulty of drawing firm conclusions from observational data alone. What it does mean is that no UK regulator has determined the risk is large enough or certain enough to restrict prescribing on that basis. The detailed page on Wegovy and blindness risk explains how the MHRA's monitoring process works and what would trigger a formal warning. Reporting any suspected side effect, including vision changes, is straightforward through the MHRA's Yellow Card service.

Pre-existing diabetic retinopathy deserves a specific mention. The SmPC for semaglutide notes that rapid improvement in blood-glucose control has historically been associated with temporary worsening of diabetic retinopathy, a separate and well-established phenomenon. Patients with retinopathy should discuss this with their prescriber before starting treatment.

Step 3: Putting this into perspective alongside Wegovy's other neurological side effects

It is worth situating vision concerns within the broader side-effect profile of semaglutide. The most common effects are gastrointestinal (nausea, vomiting, constipation, diarrhoea) which tend to be most pronounced at the start of treatment or after a dose increase and usually settle over days to a couple of weeks, as the NHS semaglutide medicines page describes in detail.

Some people also report dizziness or lightheadedness, typically linked to appetite reduction, lower caloric intake or postural blood-pressure changes, and whether Wegovy can cause lightheadedness is something that page explores in full, including why it happens and what helps. Dizziness with Wegovy is generally manageable and distinct from vision loss, but any sudden sensory change affecting the eyes, including double vision or loss of part of the visual field, warrants same-day assessment rather than watchful waiting. The NHS advises contacting 111 or seeking urgent care if you experience sudden changes in vision while on any weight-loss medicine.

If you are trying to understand how these side-effect considerations fit within the overall picture of how well Wegovy works, that page covers the clinical-trial weight-loss data alongside the risk-benefit framing that prescribers use when discussing the medicine with patients.

Step 4: What to do if you are considering Wegovy and have eye concerns

If you have a history of NAION in one eye, optic nerve disease, or are being monitored for diabetic retinopathy, raise this before starting treatment. A prescriber will weigh the cardiovascular and metabolic benefits against individual risk factors, that conversation cannot happen without knowing your full history, which is why a proper clinical assessment matters. At nume, a GPhC-registered Independent Prescriber reads every consultation personally before any prescription is issued. The process starts with a free consultation, includes photo-ID and live weight verification, and your GP is notified in line with GPhC guidance.

If you are already taking semaglutide and notice any sudden change in vision, do not attribute it to the medicine and carry on, get it assessed urgently. NAION, if that is what it is, is not reversible once established; early assessment gives the best chance of preserving sight in the unaffected eye and ruling out other treatable causes such as a transient ischaemic attack.

For people curious about semaglutide more broadly before deciding whether to explore treatment, the semaglutide overview page covers the mechanism, the licensed uses, and how private prescribing works in the UK. When you are ready to discuss your own history and health picture with a clinical team, starting a free consultation is the next step.